Bangalore: India's biotechnology major Biocon Ltd 's subsidiary Syngene has entered into partnership with Bristol-Myers Squibb, one of the world's leading pharmaceutical firms, to provide research and development (R&D) services for development of drugs.
With this partnership, Bristol-Meyers Squibb will be able to increase its scope in the Indian market in areas such as medicinal chemistry, biology, drug metabolism and pharmaceutical development.
"The new research facility will mark a significant step forward in our evolution as a valuable partner to the global pharmaceutical industry," chairperson of the Biocon Group, Kiran Mazumdar-Shaw told a press conference here Wednesday.
Syngene provides customised R&D services to pharmaceutical and biotechnology companies on a strong platform of confidentiality and intellectual property protection.
"Bristol-Myers Squibb has been a valued customer of Syngene since 1998. This enhanced partnership with Bristol-Myers Squibb heralds a new phase in Syngene's advancing capabilities in providing high end services in discovery research," added chief operating officer, Syngene International, Goutom Das.
Comments
0 comment